Skip to main content

Table 1 Efficacy of a single oral dose of a novel chewable tablet (Simparica Trio™) containing sarolaner, moxidectin, and pyrantel pamoate against induced L4 larval and immature adult (L5) Ancylostoma caninum infections in dogs

From: Efficacy of Simparica Trio™, a novel chewable tablet containing sarolaner, moxidectin and pyrantel, against induced hookworm infections in dogs

Study

Isolate origin

Stage at time of treatment

Day of inoculationa

Day of treatment

Day of worm recovery

Treatment groupb

n

No. of infected dogs

Worm count range

Geometric mean worm count

Efficacy compared to placebo

% Efficacy

Test statistic

1

Europe

L4 larvae

− 7

0

7

Placebo

9

9

11–36

21.0

Simparica Trio™

9

0

0

0

100

t(7) = 21.62

P < 0.0001

2

USA

L4 larvae

8

Placebo

8

8

4–17

9.2

Simparica Trio™

8

1

0–2

0.1

98.4

t(7) = 12.76

P < 0.0001

3

USA

Immature adults (L5)

− 11

0

7

Placebo

8

8

110–260

209.9

Simparica Trio™

8

3

0–3

0.5

99.8

t(7) = 22.77

P < 0.0001

4

Europe

Immature adults (L5)

Placebo

8

8

23–41

29.6

Simparica Trio™

8

0

0

0

100

t(7) = 47.93

P < 0.0001

  1. aEach dog was inoculated with 200 ± 50 L3 A. caninum
  2. bSimparica Trio™ provided minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt)
  3. Abbreviation: n, number of animals per group